In particular, a composition for breast augmentation that includes a composition promoting an increase in subcutaneous tissue, wherein the promoting composition aims at accumulating and increasing adipose tissue under the skin of a breast by generating and increasing the adipose tissue around a mammary gland and enables recovery of autologous tissue and recovery of appearance by a safe and natural process, and a method for breast augmentation are provided. A composition promoting an increase in subcutaneous tissue that contains autologous plasma and a basic fibroblast growth factor (b-FGF), in particular, a composition for breast augmentation is provided. A composition for breast augmentation that includes the above-described composition promoting an increase in subcutaneous tissue that further contains fat is provided. Specifically, a composition for breast augmentation that includes the above-described composition promoting an increase in subcutaneous tissue, wherein the fat is in the form of a lipid emulsion and the lipid emulsion is an oil-in-water lipid emulsion produced by emulsifying fat and oil in the presence of an emulsifier, and a method for breast augmentation by using the composition are provided. An injection unit of the composition for breast augmentation is also provided.

The present invention provides methods for preparing modified blood clots comprising removal of the cellular content of the blood clots. The invention further provides uses of the modified blood clots as therapeutic agents and as delivery vehicles for cells, bio-molecules and other agents.

An autologous bone graft substitute composition for inducing new bone formation, promoting bone growth and treating bone defects, a method of preparation thereof, and a method of inducing or promoting bone growth by treatment of a bone with an autologous bone graft substitute composition. The composition includes autologous blood; one or more analogs of an osteogenic bone morphogenetic protein selected from BMP-6, BMP-2, BMP-7, BMP-4, BMP-5, BMP-8, BMP-9, BMP-12, and BMP-13, and combinations thereof; and a compression resistant matrix selected from the group consisting of a bone autograft, bone allograft, hydroxyapatite, tri-calcium phosphate, and combinations thereof. The autologous blood forms a coagulum gel comprising a fibrin-meshwork reinforced with the compression resistant matrix and containing the osteogenic bone morphogenetic protein which is released over a sustained period.

Compositions are provided herein comprising a coacervate of a polycationic polymer, a polyanionic polymer, and platelet-rich plasma and/or serum, or a fraction or concentrate thereof. The composition is useful in wound healing. Compositions also are provided that comprise a hydrogel comprising TIMP-3; and a complex of a polycationic polymer, a polyanionic polymer, FGF-2 and SDF-1 embedded in the hydrogel, which is useful in treating a myocardial infarction.

A resorbable device for the reconstruction of cartilage includes a piece of fabric made of PGA, which can be impregnated with patient blood and fixable to a bone at an articulation, the piece preferably being impregnated with collagen.

An object of the present invention is to provide a fibrin composition manufactured by a method as a substitute for a method for manufacturing platelet-rich fibrin (PRF) triggered by the activation of a coagulation factor, a substrate for regenerative medicine using the fibrin composition, a method for manufacturing a fibrin composition, and a kit for being used in the method. According to the present invention, there is provided a fibrin composition including blocks, which each include a protein having repetitive Arg-Gly-Asp sequences derived from human collagen, fibrin, and platelets.

Various embodiments disclosed relate to curable calcium phosphate compositions for use with porous structures and methods of using the same. In various embodiments, the present invention provides a curable calcium phosphate composition or a cured product thereof, with the curable calcium phosphate composition including calcium phosphate and a perfusion modifier. In various embodiments, the present invention provides an apparatus comprising a porous structure at least partially in contact with the curable calcium phosphate composition or a cured product thereof. The porous structure can include a porous substrate including a plurality of ligaments that define pores of the porous substrate, and a biocompatible metal coating on the plurality of ligaments of the porous substrate.

Various embodiments disclosed relate to curable calcium phosphate compositions for use with porous structures and methods of using the same. In various embodiments, the present invention provides a curable calcium phosphate composition or a cured product thereof, with the curable calcium phosphate composition including calcium phosphate and a perfusion modifier. In various embodiments, the present invention provides an apparatus comprising a porous structure at least partially in contact with the curable calcium phosphate composition or a cured product thereof. The porous structure can include a porous substrate including a plurality of ligaments that define pores of the porous substrate, and a biocompatible metal coating on the plurality of ligaments of the porous substrate.

A composition includes Purified Exosome Product (PEP) and a pharmaceutically acceptable carrier that includes a surgical glue or tissue adhesive. In some embodiments, the PEP includes spherical or spheroid exosomes having a diameter no greater than 300 nm. In some embodiments, the PEP includes from 1% to 20% CD63.sup. exosomes and from 80% to 99% CD63.sup.+ exosomes. In some embodiments, the PEP includes at least 50% CD63.sup. exosomes. The composition may be applied to injured peripheral nervous tissue to promote growth of peripheral nervous tissue and/or treat the injured peripheral nervous tissue. The peripheral nervous tissue may be autologous or may be allogeneic.

Provided herein is a platelet-rich plasma (PRP) product comprising activated PRP releasate in which a deleterious factor that inhibits growth of a target tissue type is removed. The PRP product is useful in growth or regeneration of tissue of the target tissue type, such as muscle, cartilage, or bone. Also provided herein is a method of making a tissue-customized PRP product for growth or repair of a target tissue, such as muscle, cartilage, or bone, comprising removing a deleterious factor for the growth of the target tissue from activated PRP releasate.